Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.
about
Impact of Non-Pulmonary Visceral Metastases in the Prognosis and Practice of Metastatic Testicular Germ Cell TumorsHigh dose chemotherapy with stem cell support in the treatment of testicular cancerAdvances in the treatment of testicular cancerSurveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experienceEtiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosisContemporary management of stage I and II seminoma.Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia.Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial.Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Sequential bilateral testicular tumours presenting with intervals of 20 years and more.CK19 is a sensitive marker for yolk sac tumours of the testisPersonalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction.Controversies in the management of clinical stage I testicular seminoma.Testicular seminoma clinical stage 1: treatment outcome on a routine care level.Swarm-based medicineTreatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship.Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.SEOM clinical guidelines for the management of germ cell testicular cancer (2016).Testicular cancer: biology and biomarkers.Management of clinical stage I nonseminomatous germ cell tumors.High-dose chemotherapy for germ cell tumors: do we have a model?Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.Cisplatin resistance in germ cell tumours: models and mechanisms.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Testicular manifestation of a transformed mycosis fungoides.Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization.Management of stage I testicular germ cell tumours.High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?Dismantling the present and future threats of testicular cancer: a grounded theory of positive and negative adjustment trajectories.The epigenetics of testicular germ cell tumors: looking for novel disease biomarkers.Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.Long-term cardiovascular complications in stage I seminoma patients.Vitamin D status among long-term survivors of testicular cancer.Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test).
P2860
Q26740605-14E7E3D0-0776-4A6B-9B1B-1721FA7C4F25Q26771162-2D26A992-0249-406A-8022-B3560D4FF818Q26773626-92AAE9E5-1B52-4FF3-AF5B-E7CFAE33F0E2Q26865862-61A142FC-A73B-4FED-9962-31F5222E33D2Q26991452-1137A71C-BEA6-4DD4-B95D-503DCA65340FQ30352886-772460CE-E454-4F2C-AEB1-81D740B010B9Q30844164-008A326A-65D5-49AE-B2D6-982F39840738Q33590396-2EA42841-D47C-4F17-81F4-B9A64A9BD8B0Q33877463-754C213F-C47B-469B-82A1-2C1F82D2DC42Q34886445-68901ED9-0925-479B-A653-D7644FAA2763Q35062918-B6777099-EAE5-4EE5-97C8-A18F3A9492A7Q35258032-07D44EDB-B40E-4088-A33D-A50B20499327Q35456754-9C69FF86-055B-4BB7-8ABE-67E0754B343DQ35607629-94386545-5627-4128-8CD4-8B4372856815Q36840698-B4C62411-349C-4C52-84BB-399096DD73D5Q36985245-8AAF41D0-60B5-4E53-AD79-5312450B57CFQ37204661-B60FED18-6392-42D7-B7EF-1FBAA3761E3EQ37251177-031CB119-CEF3-4616-9DCE-093C5649CED4Q37350871-5115684C-C973-4E57-9A60-E8C68316C1FDQ37475147-AA5ECD2C-F9AB-4DE3-A854-33CAA78AB382Q38184375-74C22622-07EE-4B10-9355-B1FC521A7CF7Q38220484-F320B8F5-2C7F-4E85-B7FE-3CF78A78C0A1Q38253101-F291154E-4A4C-40B0-BFF5-7DE4E6F79CA1Q38261332-BC7898C7-0600-4C35-9BB8-F323BCD6283DQ38302534-C98A4CB5-CB34-42B5-B45C-036F00DBC0A0Q38387292-6ED0B409-DE58-45F5-92CC-51C6D868FF1EQ38629000-15089DC6-2DC9-4FFA-84E7-4734D7151ACEQ38656908-4989A7F2-4A75-4DAC-831E-AF3D02143A88Q38784326-71615A66-05EF-4362-A997-849DF6F0C7E1Q38829087-DFADFA5F-65D9-43EE-A618-1BA7D900AA78Q38861914-BBD29077-E2FC-4F7D-B208-CD89E66ABC3EQ38952121-82B54C7E-951C-414E-8C95-7F65E1D41E79Q38966419-D35871D3-4005-4064-ADE6-44CA2257647FQ38979986-054E8070-6542-4E22-8186-0EC95DF359FBQ38986489-CF4EB650-AB2F-43E5-A986-CF471DB34C06Q39093289-62615CA7-8C11-4889-94CB-83D151856F90Q39177653-753A5A9A-34D8-41FF-8056-ACD4829D27A9Q40065469-97652516-0F51-4CA5-9B62-AEB6B34B26FBQ41055710-E083908F-4A9A-47EB-9A44-22E39E56024DQ41709727-C054B0FB-0A28-4D40-ABDA-77EB7382691E
P2860
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Maintaining success, reducing ...... treatment of germ-cell cancer.
@en
Maintaining success, reducing ...... treatment of germ-cell cancer.
@nl
type
label
Maintaining success, reducing ...... treatment of germ-cell cancer.
@en
Maintaining success, reducing ...... treatment of germ-cell cancer.
@nl
prefLabel
Maintaining success, reducing ...... treatment of germ-cell cancer.
@en
Maintaining success, reducing ...... treatment of germ-cell cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Maintaining success, reducing ...... treatment of germ-cell cancer
@en
P2093
A Giwercman
A Heidenreich
C Bokemeyer
C Kollmannsberger
P2860
P304
P356
10.1093/ANNONC/MDS579
P50
P577
2012-11-14T00:00:00Z